Abstract
Abstract
Juvenile dermatomyositis (JDM) is an inflammatory myopathy with specific skinlesions. The prevalence rate is 10/10,000,000 while the prevalence rate in childrenis 3.2/10,000,000. Although the etiology is not fully understood, tissue compatibility antigens, environmental factors (viruses, drugs, etc.) and autoimmunity are often responsible. In adults, the average age of diagnosis is 40 years of age, and children usually start between 5 and 14 years of age. In children, clinical onset is mostlymild and often begins with the involvement of the proximal muscles. The most helpful feature in the diagnosis of JDM is skin findings with typical involvement. This case is presented for the purpose of reviewing and reminding the patient that the in-cidence of juvenile dermatomyositis uncommon is very rare, especially the pediatric patients who come with skin lesions, in order to make early diagnosis of the systemic examination, especially muscle system examination.
References
- Kaynaklar 1.Koler RA, Montemarano A Dermatomyositis. Am Fam Physi-cian. 2001 Nov1;64(9):1565-72. 2.Callen JP.Dermatomyositis. In: Callen JP, ed. Dermatologi-cal signs ofinternal disease. 2d ed. Saunders, 1995:13-20. 3.Steen VD, Oddis CV, Conte CG, et al. Incidence of systemicsclerosis inAllegheny County, Pennsylvania. A twenty-yearstudy of hospital-diagnosed cases, 1963-1982. Arthritis Rhe-um. 1997 Mar; 40 (3): 441-5. 4.Pachman LM. Juvenile dernatomyositis: immune-genetics, pat-hophysiology and disease expression. Rheum. Dis. Clin.North Am. 2002;28:833-57. 5.Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Derma-tol 1998;39:899920. 6.Orlow SJ, Watsky KL, Bolognia JL. Skin and bones II. J AmAcad Dermatol1991;25:447-62. 7.Pachman LM. Juvenile dermatomyositis:A clinical and immu-nologic study.J Pediatr 1980; 96: 226-34 8.Pachman LM.Juvenile dermatomyositis.Pediatr Clin North Am1995;42 (5):1071-1098 9.Meyer O, Cremer-Legmann F, Haim T, Ryckewaert A.The prin-cipleantinuclear and anti-cytoplasmic antibodies in polymyo-sitis and dermatomyositis.Study of42 cases. Presse Med. 1987Feb 7;16 (4):155-8. 10.Hengstman GJ, Brouwer R, Egberts WT, Clinical and sero-logicalcharacteristics of 125 Dutch myositis patients. Myosi-tis specific autoantibodies aid in thedifferential diagnosis ofthe idiopathic inflammatory myopathies. J Neurol. 2002Jan;249 (1):69 75. 11.Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoanti-body profiles inthe sera of European patients with myositis.Ann Rheum Dis. 2001 Feb; 60 (2): 116-23. 12.Oddis CV. Idiopathic inflammatory myopathies: a treatmentupdate. CurrRheumatol Rep. 2003 Dec;5 (6):431-6. 13.Kasteler JS, Callen JP. Low-dose methotrexate administeredweekly is aneffective corticosteroid-sparing agent for the tre-atment of the cutaneous manifestations ofdermatomyositis. JAm Acad Dermatol. 1997 Jan;36 (1):67-71. 14.Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous im-munoglobulintherapy for juvenile dermatomyositis: efficacyand safety. J Rheumatol. 2000 Oct;27 (2-10):2498-503. 15.Mehregan DR, Su WP. Cyclosporine treatment fordermatom-yositis/polymyositis.Cutis. 1993 Jan;51 (1):59-61. 16.Pachman LM. Juvenile dermatomyositis: immuno- genetics,pathophysiology and disease expression. Rheum. Dis. Clin.North Am. 2002; 28 :833-57. 17.Callen JP.Dermatomyositis. Lancet, 2000; 355 : 53-57. 18.Tezak Z et al. Gene erpession profiling in DQA1+ childrenwith untreated dermatomyositis: a novel model of pathogene-sis. J Immunol. 2002 Apr 15;168(8):4154-63 19.Dalakas MC, Hohlfeld R. Polymyositis and dermato-myosi-tis. Lancet, 2003; 36 : 971-82. 20.Cleland JA, Venzke JW. Dermatomyositis: evolution of a di-agnosis. Phys. Ther. 2003; 83: 932 45. 21.Huang JL. Long term prognosis of patient with juvenile derma-tomyositis initially treated with intravenous methylprednisolo-ne pulse theraphy. Clin Exp. Rheumatol. 1999; 17 : 621-4.
Abstract
Öz
Jüvenil Dermatomiyozit (JDM), spesifik deri lezyonları olan inflamatuvar bir miyopatidir. Erişkindeki görülme sıklığı 10/10,000,000 iken, çocuklardaki görülme sıklığı ise 3.2/10,000,000’dur. Etiyolojisi tam olarak bilinmemekle birlikte çoğu kez dokuuyumluluk antijenleri, çevresel faktörler (virus, ilaç, vb.) ve otoimmünite sorumlu tutulmaktadır. Erişkinlerde ortalama tanı konulma yaşı 40 yaş iken, çocuklarda sıklıkla 5–14 yaşları arasında başlamaktadır. Çocuklarda klinik başlangıçlar çoğunlukla sinsidir ve çoğu kez proksimal kasların tutulumlarıyla başlamaktadır. JDM’in tanı konulmasında en yardımcı özelliği tipik tutulumlarla giden cilt bulgularıdır. Bu vaka, sık görülmeyen jüvenil dermatomiyozitin iki yaşında başlamasının oldukça nadir olması, özellikle cilt lezyonları ile birlikte gelen pediatrik hastaların da tüm sistemik muayenesinin özellikle de kas sistem muayenesinin detaylı yapılarak hastalığın atlanmayıp erken tanısının konulabilmesi için literatür eşliğinde gözden geçirilmesi ve hatırlatılması amacıyla sunulmuştur.
References
- Kaynaklar 1.Koler RA, Montemarano A Dermatomyositis. Am Fam Physi-cian. 2001 Nov1;64(9):1565-72. 2.Callen JP.Dermatomyositis. In: Callen JP, ed. Dermatologi-cal signs ofinternal disease. 2d ed. Saunders, 1995:13-20. 3.Steen VD, Oddis CV, Conte CG, et al. Incidence of systemicsclerosis inAllegheny County, Pennsylvania. A twenty-yearstudy of hospital-diagnosed cases, 1963-1982. Arthritis Rhe-um. 1997 Mar; 40 (3): 441-5. 4.Pachman LM. Juvenile dernatomyositis: immune-genetics, pat-hophysiology and disease expression. Rheum. Dis. Clin.North Am. 2002;28:833-57. 5.Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Derma-tol 1998;39:899920. 6.Orlow SJ, Watsky KL, Bolognia JL. Skin and bones II. J AmAcad Dermatol1991;25:447-62. 7.Pachman LM. Juvenile dermatomyositis:A clinical and immu-nologic study.J Pediatr 1980; 96: 226-34 8.Pachman LM.Juvenile dermatomyositis.Pediatr Clin North Am1995;42 (5):1071-1098 9.Meyer O, Cremer-Legmann F, Haim T, Ryckewaert A.The prin-cipleantinuclear and anti-cytoplasmic antibodies in polymyo-sitis and dermatomyositis.Study of42 cases. Presse Med. 1987Feb 7;16 (4):155-8. 10.Hengstman GJ, Brouwer R, Egberts WT, Clinical and sero-logicalcharacteristics of 125 Dutch myositis patients. Myosi-tis specific autoantibodies aid in thedifferential diagnosis ofthe idiopathic inflammatory myopathies. J Neurol. 2002Jan;249 (1):69 75. 11.Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoanti-body profiles inthe sera of European patients with myositis.Ann Rheum Dis. 2001 Feb; 60 (2): 116-23. 12.Oddis CV. Idiopathic inflammatory myopathies: a treatmentupdate. CurrRheumatol Rep. 2003 Dec;5 (6):431-6. 13.Kasteler JS, Callen JP. Low-dose methotrexate administeredweekly is aneffective corticosteroid-sparing agent for the tre-atment of the cutaneous manifestations ofdermatomyositis. JAm Acad Dermatol. 1997 Jan;36 (1):67-71. 14.Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous im-munoglobulintherapy for juvenile dermatomyositis: efficacyand safety. J Rheumatol. 2000 Oct;27 (2-10):2498-503. 15.Mehregan DR, Su WP. Cyclosporine treatment fordermatom-yositis/polymyositis.Cutis. 1993 Jan;51 (1):59-61. 16.Pachman LM. Juvenile dermatomyositis: immuno- genetics,pathophysiology and disease expression. Rheum. Dis. Clin.North Am. 2002; 28 :833-57. 17.Callen JP.Dermatomyositis. Lancet, 2000; 355 : 53-57. 18.Tezak Z et al. Gene erpession profiling in DQA1+ childrenwith untreated dermatomyositis: a novel model of pathogene-sis. J Immunol. 2002 Apr 15;168(8):4154-63 19.Dalakas MC, Hohlfeld R. Polymyositis and dermato-myosi-tis. Lancet, 2003; 36 : 971-82. 20.Cleland JA, Venzke JW. Dermatomyositis: evolution of a di-agnosis. Phys. Ther. 2003; 83: 932 45. 21.Huang JL. Long term prognosis of patient with juvenile derma-tomyositis initially treated with intravenous methylprednisolo-ne pulse theraphy. Clin Exp. Rheumatol. 1999; 17 : 621-4.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | makale |
| Authors | |
| Publication Date | September 10, 2017 |
| Published in Issue | Year 2017 Volume: 9 Issue: 5 |
